Withanolides: The Active Compounds and Their Mechanisms
Withanolides are a class of C28 steroidal lactones unique to the Withania genus. Over 300 have been isolated from W. somnifera, but the pharmacologically most-studied include:
- Withanolide A: The primary cortisol-modulating compound — interacts with glucocorticoid receptor (GR) signaling and modulates HPA axis activity. Also has neurotrophic activity (promotes axon and dendrite outgrowth) via induction of BDNF and nerve growth factor (NGF).
- Withaferin A: The most studied anticancer withanolide — inhibits proteasome activity, NF-κB, and vimentin (cytoskeletal protein important in cancer metastasis). At supplement doses in humans, withaferin A concentrations are well below cytotoxic thresholds and may contribute to anti-inflammatory effects. Higher in Sensoril (leaf extract) than KSM-66 (root only).
- Withanolide D: The primary GABA-A receptor modulator — acts at the benzodiazepine binding site of GABA-A receptors (same site as benzodiazepines and alcohol, but with much weaker affinity). This is the proposed mechanism for ashwagandha's anxiolytic and sleep-onset effects. Does not produce dependence at dietary supplement doses.
- Sitoindosides VII–X and withanoside IV: Contribute to adaptogenic effects and memory enhancement; sitoindosides activate acetylcholine signaling in the hippocampus, supporting cognitive function claims.
HPA Axis Modulation: The Core Adaptogenic Mechanism
The HPA (hypothalamic-pituitary-adrenal) axis is the body's central stress response system. Under chronic stress, sustained CRH → ACTH → cortisol signaling produces elevated baseline cortisol, disrupted cortisol diurnal rhythm, and eventual HPA dysregulation. Ashwagandha appears to act at multiple HPA axis levels:
- Reduction of CRH (corticotropin-releasing hormone) expression in the hypothalamus
- Modulation of ACTH release from the pituitary (possibly via glucocorticoid receptor sensitization — restoring negative feedback on the HPA axis)
- Direct anti-inflammatory effects in adrenal tissue reducing excessive cortisol synthesis
- GABA-A receptor activation in limbic system structures (amygdala, hippocampus) reducing the perceived stress signal driving HPA activation
The net effect: restored cortisol diurnal rhythm (high morning, low evening) rather than a flat, chronically elevated baseline — which is what's typically seen in chronic stress. This is why ashwagandha reduces cortisol in chronically stressed individuals but does not cause clinically significant cortisol suppression in people with normal cortisol patterns.
KSM-66 vs Sensoril: Which Extract for Which Goal
KSM-66 (Ixoreal Biomed) uses an aqueous-alcoholic extraction process applied exclusively to the root of W. somnifera. It achieves ≥5% total withanolides by HPLC with minimal withaferin A content (root has less withaferin A than leaves). KSM-66 is the most clinically studied extract — Chandrasekhar 2012, Wankhede 2015, Choudhary 2017 (cognition), and most major RCTs used KSM-66. The root-only extraction aligns with traditional Ayurvedic use (Charaka Samhita specifies root preparations). Standard research dose: 300–600mg/day.
Sensoril (Natreon) uses a water and ethanol extraction from both root and leaf tissue. The dual-source extraction achieves ≥10% total withanolides with a higher proportion of withaferin A and oligosaccharides. Sensoril has been studied specifically for cardiorespiratory endurance (Choudhary 2015), sleep (Langade 2019), and stress (Auddy 2008). The higher withaferin A content may contribute to stronger anti-inflammatory effects. Standard research dose: 250–500mg/day (lower per-dose due to higher withanolide concentration).
| Study / Effect | Extract | Dose | Duration | Key Outcome |
|---|---|---|---|---|
| Cortisol reduction (Chandrasekhar 2012) | KSM-66 | 300mg x 2/day | 8 weeks | −27.9% serum cortisol; −44% PSS score; −76% DASS anxiety; n=64 chronically stressed adults |
| Testosterone + muscle (Wankhede 2015) | KSM-66 | 300mg x 2/day | 8 weeks | +17% testosterone; +1.5× strength gains; lower cortisol −18%; n=57 resistance-trained men |
| Sleep latency + quality (Langade 2019) | Sensoril | 300mg x 2/day | 10 weeks | −6 min sleep onset; +35 min sleep time; improved PSQI; lower morning cortisol; n=150 |
| Thyroid hormones (Sharma 2018) | KSM-66 | 600mg/day | 8 weeks | +19.6% T4; +41.5% T3 in bipolar disorder patients; thyroid peroxidase upregulation proposed |
| Cognitive function (Choudhary 2017) | KSM-66 | 300mg x 2/day | 8 weeks | Improved immediate memory, general memory, executive function, attention; n=50 healthy adults |
| VO₂max / endurance (Choudhary 2015) | Sensoril | 500mg/day | 8 weeks | +7% VO₂max vs placebo; improved treadmill time to exhaustion; n=50 healthy athletic adults |
Ashwagandha Dosing Protocol by Goal
- Cortisol reduction and stress resilience — 600mg/day KSM-66, split dosing: 300mg with breakfast + 300mg with dinner. The evidence base is strongest at this dose — it mirrors the Chandrasekhar 2012 protocol exactly. Effects accumulate over 4–8 weeks; do not judge efficacy after less than 4 weeks of consistent use. Morning dosing ensures adequate withanolide levels during peak cortisol hours (7–9 AM) when HPA modulation is most relevant.
- Sleep improvement — 300–600mg Sensoril (or KSM-66) in the evening: Langade 2019 used 300mg Sensoril x 2/day, but the primary sleep benefit likely comes from the evening dose (GABA-A receptor modulation + reduced evening cortisol arousal). A single 300–600mg dose 30–60 min before bed is a commonly used protocol. Ashwagandha is not a sedative in the traditional sense — it doesn't cause drowsiness acutely; it reduces hyperarousal and cortisol-driven sleep disruption over time.
- Testosterone and strength — 300mg KSM-66 x 2/day during resistance training blocks: The Wankhede 2015 protocol used 600mg/day alongside a structured resistance training program. The testosterone effect is likely indirect — via cortisol reduction (cortisol is catabolic and competitively suppresses testosterone synthesis from the same pregnenolone precursor). Users report the most notable effects during high-stress training periods when cortisol:testosterone ratio is dysregulated. In men with normal stress levels and training recovery, effects will be more modest.
- Cycle length and breaks: No established safety data on continuous year-round use exists beyond 12-week RCTs. Most practitioners recommend 8–12 week use cycles followed by 2–4 week breaks. Ashwagandha does not appear to cause dependence (unlike benzodiazepines that act more strongly on the same GABA-A site), but cycling prevents potential tolerance to withanolide effects on GR and GABA-A receptors.
- Contraindications and cautions: Avoid in pregnancy (uterotonic effects — traditional use as an abortifacient at high doses). Use with caution in autoimmune thyroid disease (Hashimoto's) — the thyroid-stimulating effects could worsen autoimmune thyroid inflammation in susceptible individuals. May potentiate sedatives, benzodiazepines, and barbiturates via GABA-A synergy. Rare cases of liver injury have been reported with ashwagandha supplements — the causal relationship is not established but warrants monitoring liver enzymes in long-term users.
Look for: "KSM-66" explicitly listed on the label — generic ashwagandha extracts vary widely in withanolide content and may not replicate clinical trial results. Target 300mg KSM-66 per serving (providing ~15mg withanolides at 5% standardization). Well-regarded options: Jarrow Formulas Ashwagandha KSM-66, NOW Foods KSM-66, Thorne Botanicals Ashwagandha. Avoid products listing only "Withania somnifera root powder" without standardization — these are essentially ground root with unknown withanolide content.